Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 11/14/25 → 10/29/27 |
Funding
- Johnson and Johnson Enterprise Innovation Incorporated: $2.00
25-HN-44-JJ (NANORAY-312): A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced H
- Yang, Eddy (PI)